Trial Profile
A Phase 3 trial of niraparib in combination with an anti-PD-1 antibody in comparison to niraparib in first-line maintenance treatment of patients with advanced ovarian cancer who have responded to platinum induction therapy
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 03 Apr 2017 New trial record